This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
New drug approvals in acute myeloid leukemia: what’s the best end point?
Leukemia Open Access 18 December 2015
-
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Leukemia Open Access 05 February 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Acknowledgements
This work was supported by funding from the NIMR Biomedical Research Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Goldman, J., Gale, R. What does MRD in leukemia really mean?. Leukemia 28, 1131 (2014). https://doi.org/10.1038/leu.2013.318
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.318
This article is cited by
-
Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert
Bone Marrow Transplantation (2021)
-
Prof. Anton Hagenbeek 1948–2021: Father of MRD and Lymphoma Expert
Leukemia (2021)
-
The not so new history of storing bone marrow
Bone Marrow Transplantation (2020)
-
Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia
Current Treatment Options in Oncology (2019)
-
Measurable residual disease testing in acute myeloid leukaemia
Leukemia (2017)